PHILADELPHIA, Dec. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc
(NYSE: GSK) today announced the following executive appointments and
changes:
-- Andrew Witty, CEO Designate, and Chris Viehbacher, President US
Pharmaceuticals, have been appointed Executive Directors and will join
the Board of the Company with effect from 31st January 2008.
-- Eddie Gray, currently Senior Vice President and General Manager
Pharmaceuticals UK, will succeed Andrew Witty as President,
Pharmaceuticals Europe for GlaxoSmithKline. Eddie will assume his new
position on 1st January 2008.
-- David Stout, currently President of Pharmaceuticals, will leave the
company in February 2008.
Commenting on the changes, Sir Christopher Gent, Chairman, said: "I am
very pleased that both Andrew and Chris will be joining the Board. In doing
so, we have increased the overall number of executive directors on the
Board, and ensured that it remains strongly aligned to GSK's strategy and
operational performance."
JP Garnier, Chief Executive Officer, said: "I would like to thank David
sincerely for his significant contribution to GSK and for the support he
has given me over many years. We wish him well in his future endeavors.
Andrew and I would also like to congratulate Eddie on his appointment and
welcome him to the Corporate Executive Team. We wish him every success in
managing our European pharmaceuticals business."
Notes to Editors
Eddie Gray: Biography
Eddie Gray was appointed Senior Vice President and General Manager,
Pharmaceuticals UK for GlaxoSmithKline in 2001. He is a member of the
Pharmaceuticals Europe Executive Team. Previously, he was Vice President &
General Manager, SmithKline Beecham Pharmaceuticals, Canada, and a member
of SmithKline Beecham's Executive Management Team for North America.
Eddie joined SmithKline Beecham in 1988 as National Sales Manager. He
held various positions in the UK company of increasing responsibility,
including Head of Hospital Sales, Marketing Manager for Anti-Infective
products and Business Unit Director for the UK Pharmaceuticals General
Medicine business before moving to the US, where he assumed responsibility
for Market Research for the US Pharmaceuticals business. He later became
Vice President & Director of Anti-Infectives Marketing, then Vaccines
Marketing in the US, before assuming his role in Canada.
Eddie serves on the Board of Management of the Association of the
British Pharmaceutical Industry (ABPI) and chairs the ABPI Economic
Strategy Group. He is an advisory board member of Opportunity Now, an
organization for employers who are committed to creating an inclusive
workplace for women; and a Trustee of Project HOPE UK which aims to make
health care available for people around the globe, especially children.
Eddie holds an honors degree in Chemistry and Management Studies from
the University of London, and an MBA from the Cranfield School of
Management in the UK. He is married with three daughters.
GlaxoSmithKline -- one of the world's leading research-based
pharmaceutical and healthcare companies -- is committed to improving the
quality of human life by enabling people to do more, feel better and live
longer. For company information, visit GlaxoSmithKline on the World Wide
Web at http://www.gsk.com.
SOURCE GlaxoSmithKline plc
 back to top
Related links:
http://www.gsk.com
http://www.prnewswire.com/comp/801350.html /
CONTACT:
US Media inquiries: Nancy Pekarek,
+1-215-751-7709, or Mary Anne Rhyne, +1-919-483-2839, UK Media
inquiries: Phil Thomson, Alice Hunt, Joss Mathieson, or Claire
Brough, (020) 8047 5502; US Analyst, Investor inquiries: Frank
Murdolo, +1-215-751-7002, or Tom Curry, +1-215-751-5419, European
Analyst, Investor inquiries: David Mawdsley, (020) 8047 5564, or
Sally Ferguson,(020) 8047 5543, all of GlaxoSmithKline plc
|
